Ubs Group Ag Annovis Bio, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 160,876 shares of ANVS stock, worth $416,668. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160,876
Previous 48,736
230.1%
Holding current value
$416,668
Previous $245,000
1.63%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ANVS
# of Institutions
55Shares Held
2.06MCall Options Held
88.1KPut Options Held
188K-
Vanguard Group Inc Valley Forge, PA648KShares$1.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$474,7130.0% of portfolio
-
Two Sigma Investments, LP New York, NY166KShares$430,5070.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA128KShares$330,7550.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$260,8360.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $21.1M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...